Trending...
- BESTBUYSTORE opens its dropshipping model to independent merchants
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal's commercial team will report directly to Chief Executive Officer Krish Krishnan on an interim basis as the company initiates a search for Ms. Chien's replacement.
"I look forward to working with our commercial leadership team and expect continued progress of our pre-launch activities without interruption," said Krish Krishnan, Chief Executive Officer, Krystal Biotech. "Our GEM-3 trial is advancing as planned and we anticipate completing enrollment early next year. While the COVID-19 environment has been a challenge to everyone in the industry, I am pleased that our careful planning has kept patient enrollment on track across diverse geographical sites in the US."
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction. For more information, please visit http://www.krystalbio.com.
More on The PennZone
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal's product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec ("B-VEC"), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystal's plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystal's existing cash resources; the unanticipated impact of COVID-19 on Krystal's business operations, pre-clinical activities and clinical trials; and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption "Risk Factors" in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's views as of any date subsequent to the date of this release.
More on The PennZone
"I look forward to working with our commercial leadership team and expect continued progress of our pre-launch activities without interruption," said Krish Krishnan, Chief Executive Officer, Krystal Biotech. "Our GEM-3 trial is advancing as planned and we anticipate completing enrollment early next year. While the COVID-19 environment has been a challenge to everyone in the industry, I am pleased that our careful planning has kept patient enrollment on track across diverse geographical sites in the US."
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction. For more information, please visit http://www.krystalbio.com.
More on The PennZone
- One in three Americans may have lost track of retirement savings from a previous job
- Political Concerns Drive US Investors to Golden Visas
- The Truth Makers: The Quantum Lie Turns a Presidential Bribery Video Into a Crisis of Reality
- 2027 Health Insurance Open Enrollment
- Ryan J. Murphy Named as 2026 Irish Legal 100 Honoree
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal's product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec ("B-VEC"), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystal's plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystal's existing cash resources; the unanticipated impact of COVID-19 on Krystal's business operations, pre-clinical activities and clinical trials; and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption "Risk Factors" in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's views as of any date subsequent to the date of this release.
More on The PennZone
- Gahl Sasson Releases "Agents of Chaos & Angels of Change: The Astrology of 2027
- Joe "LIL Snuff" Perri Takes Center Stage as SMACK Fighting Championships 2 Returns to Philly
- Tek84 Unveils New Brand Identity Built to Magnify What Security Officers Can Do
- CoreVar Announces Cooking with AI, an Eight-Topic Live Webinar Series
- Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026
0 Comments
Latest on The PennZone
- Sycamore Dove Releases "Loving Every Moment"
- Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Nashville
- Soft & Sweet Unveils New Studio Location and Website for All-Natural Sugaring in Las Vegas
- Beyond Popularity Rankings, The World's No.1 Superstar® Wins Best Pop Music Video for "Under Your Spell"
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
- ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
- New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
- RAS AP Consulting Releases Educational Resource to Help Organizations Prepare for IRS FIRE-to-IRIS Transition
- York County Is an EPA Radon Zone 1. Here Is What Homeowners Should Know Before Testing
- What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
- Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
- New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
- Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
- Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
- Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event